Profitability: A Mixed Blessing for Celltech
Celltech's early profits have come from unexciting, low growth specialty pharma products rather than from a breakthrough in its innovative biotechnology pipeline. Now, the challenge for new CEO Göran Ando is to prove that Celltech's focus remains R&D, not specialty pharmaceuticals. With few promising late-stage in-house projects other than CDP 870, generic threats to the revenue source, and the straitjacket that comes with profitability, Ando has plenty on his plate. But his experience, both broadly within the industry and with CDP 870 in particular, suggest he's well placed to take Celltech to a new level of profitability.
You may also be interested in...
Morphosys is a rare biotech company in that it is both an R&D driven enterprise and is profitable at the same time, thanks mostly to a variety of antibody discovery deals it has signed over the years with pharmaceutical partners. As the company brings more product candidates into the clinic will its profitability become a strategic liability, imposing limits on how much it can spend to drive products forward?
Peter Fellner, PhD, recently appointed chairman of British Biotech and outgoing CEO of Celltech Group says more of Europe's biotechs need to do what Celltech has done: find a revenue-generating business model.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.